Antidepressant effects of selective adenosine receptor antagonists targeting the A1 and A2A receptors administered jointly with NMDA receptor ligands: behavioral, biochemical and molecular investigations in mice
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Antidepressant effects of selective adenosine receptor antagonists targeting the A1 and A2A receptors administered jointly with NMDA receptor ligands: behavioral, biochemical and molecular investigations in mice ; volume:76 ; number:5 ; day:25 ; month:7 ; year:2024 ; pages:1012-1031 ; date:10.2024
Pharmacological reports ; 76, Heft 5 (25.7.2024), 1012-1031, 10.2024
- Creator
-
Szopa, Aleksandra
Bogatko, Karolina
Serefko, Anna
Herbet, Mariola
Ostrowska-Leśko, Marta
Wróbel, Andrzej
Radziwoń-Zaleska, Maria
Dudka, Jarosław
Wlaź, Piotr
Poleszak, Ewa
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s43440-024-00627-z
- URN
-
urn:nbn:de:101:1-2411252102219.301638006711
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Szopa, Aleksandra
- Bogatko, Karolina
- Serefko, Anna
- Herbet, Mariola
- Ostrowska-Leśko, Marta
- Wróbel, Andrzej
- Radziwoń-Zaleska, Maria
- Dudka, Jarosław
- Wlaź, Piotr
- Poleszak, Ewa
- SpringerLink (Online service)
Other Objects (12)
A2A adenosine receptor antagonists: are triazolotriazine and purine scaffolds interchangeable?
Leukotriene Receptor Antagonists
Adenosine A2A receptor antagonists act at the hyperoxic phase to confer protection against retinopathy
A2A adenosine receptor interacting partners (interactome)
Piperazine‐based P2X4 receptor antagonists
Mineralocorticoid receptor antagonists in dialysis patients
Why are mineralocorticoid receptor antagonists cardioprotective?
Neurokinin 1 Receptor Antagonists for Pruritus
Characterization of the trigeminovascular actions of several adenosine A2A receptor antagonists in an in vivo rat model of migraine
A covalent antagonist for the human adenosine A2A receptor
Neuroprotection by adenosine in the brain: From A1 receptor activation to A2A receptor blockade
Azologization of serotonin 5-HT3 receptor antagonists
A2A adenosine receptor antagonists: are triazolotriazine and purine scaffolds interchangeable?
Leukotriene Receptor Antagonists
Adenosine A2A receptor antagonists act at the hyperoxic phase to confer protection against retinopathy
A2A adenosine receptor interacting partners (interactome)
Piperazine‐based P2X4 receptor antagonists
Mineralocorticoid receptor antagonists in dialysis patients
Why are mineralocorticoid receptor antagonists cardioprotective?
Neurokinin 1 Receptor Antagonists for Pruritus
Characterization of the trigeminovascular actions of several adenosine A2A receptor antagonists in an in vivo rat model of migraine
A covalent antagonist for the human adenosine A2A receptor
Neuroprotection by adenosine in the brain: From A1 receptor activation to A2A receptor blockade
Azologization of serotonin 5-HT3 receptor antagonists
A2A adenosine receptor antagonists: are triazolotriazine and purine scaffolds interchangeable?
Leukotriene Receptor Antagonists
Adenosine A2A receptor antagonists act at the hyperoxic phase to confer protection against retinopathy
A2A adenosine receptor interacting partners (interactome)
Piperazine‐based P2X4 receptor antagonists
Mineralocorticoid receptor antagonists in dialysis patients
Why are mineralocorticoid receptor antagonists cardioprotective?
Neurokinin 1 Receptor Antagonists for Pruritus
Characterization of the trigeminovascular actions of several adenosine A2A receptor antagonists in an in vivo rat model of migraine
A covalent antagonist for the human adenosine A2A receptor
Neuroprotection by adenosine in the brain: From A1 receptor activation to A2A receptor blockade